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ABSTRACT
Objective: Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction (NMJ) caused by antibodies that attack components 
of the postsynaptic membrane, impair neuromuscular transmission, and lead to weakness and fatigue of skeletal muscle. Acetylcholine is also used 
as a neurotransmitter in the autonomic nervous system. Striated cardiac muscle can be a target for immune attack manifesting as heart failure, 
arrhythmia, and sudden death. Involvement of the heart rate (HR) has been claimed and reported, but a causal connection between MG and altered 
cardiac function has not been found.
Results: From the results, the study found that sympathetic activity of HR variability in EAMG injected with rocuronium 10 mg/kg body weight (BW) 
in 10 min significantly found increasing in measures of short-term variations in HR variability, indicating parasympathetic impairment.
Conclusion: We conclude that in MG, cholinergic transmission is affected more diffusely than previously thought. Furthermore, AI was given orally 
30 mg/kg BW has an effect similar to the injecting of prostigmine 10 mg/kg BW that can reduce HR. Driven by the fact that the pharmacological 
treatment of MG is unsatisfied, it needs the therapeutic development for MG using herbal ingredients of AI. This means that the AI compositions 
containing anti-MG whose composition should be investigated for the next research.
Keywords: Myasthenia gravis, Extract Acalypha indica Linn., Acetylcholine receptor antibody, Autoimmune disease, Neuromuscular junction, 
Heart rate.
INTRODUCTION
Myasthenia gravis (MG) is an autoimmune neuromuscular transmission 
disorder characterized by loss of acetylcholine receptor (AChR) 
functionality arising from the action of AChR antibody (Ab) [1,2]. 
Antibodies to the nicotinic AChR destroy the AChR, thus leading to 
defective neuromuscular transmission of electrical impulse and to 
muscle weakness. Acetylcholine is an organic chemical that functions 
in the brain and body of many types of animals, including humans, as 
a neurotransmitter used at the neuromuscular junction (NMJ). This 
property means that drugs that affect cholinergic systems can have 
very dangerous effects ranging from paralysis to convulsions [3]. 
Acetylcholine is also used as a neurotransmitter in the autonomic 
nervous system, both as an internal transmitter for the sympathetic 
nervous system and as the final product released by the parasympathetic 
nervous system. Striated cardiac muscle can be a target for immune 
attack manifesting as heart failure, arrhythmia, and sudden death. 
Involvement of the heart has been claimed and reported, but a causal 
connection between MG and altered cardiac function has not been 
found. Furthermore, the sympathetic activity of HR variability did not 
differ significantly between patients and controls; however, a significant 
decrease in measures of short-term vagal variations in HR variability 
was noted indicating parasympathetic impairment [4,5]. Mygland 
et al. [6] demonstrated that the existence of heart muscle antibodies 
was related to a type of MG, in finding such antibodies in MG patients 
with thymoma and late-onset MG, but not in early-onset MG. These 
heart muscle antibodies were shown to be specific for MG. Lately, the 
discovery of antibodies to the muscle-specific tyrosine kinase (MuSK) 
has identified a subgroup of MG patients with rather distinct clinical 
characteristics [7]. Cardiac function has not been examined specifically 
in MuSK-positive MG patients. However, MG is known to involve other 
body systems including the heart. Cardiac involvement in MG may take 
several forms, ranging from asymptomatic electrocardiograph (ECG) 
changes to ventricular tachycardia, myocarditis, conduction disorders, 
heart failure, and sudden death [8]. Furthermore, MG patients have 
a higher prevalence of cardiac manifestations in the presence of 
thymoma (10–15%) [9]. Since the preganglionic neuron diverges the 
information to more neurons in the case of a sympathetic system in 
contrast to that of a parasympathetic system where the preganglionic 
fibers contact a few postganglionic neurons, the impact can be 
postulated to be small in case of a sympathetic nervous system than 
a parasympathetic function [10]. The cardiovascular effects of these 
neuromuscular blocking agents have been investigated in different 
studies. The experimental autoimmune MG (EAMG) can be induced 
in mice and rats of susceptible strains that show clinical symptoms 
mimicking the human disease. While the prevailing clinical finding of 
MG is muscle fatigue and weakness and autonomic dysfunction [11-13]. 
Both positive inotropic and chronotropic effects have been reported 
after pancuronium administration [14,15] by increased HR and 
arterial blood pressure [16,17]. The EAMG is most frequently detected 
by clinical evaluation of muscle weakness of the mouse and the 
ability of neostigmine (an acetylcholinesterase inhibitor) to reverse 
the manifestations of a disease. Drugs that competitively inhibit 
acetylcholinesterase (e.g., neostigmine, physostigmine, or primarily 
pyridostigmine) are effective in treating this disorder. They allow 
endogenously released acetylcholine more time to interact with its 
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Methods: For this study of experimental autoimmune MG (EAMG) is used rocuronium, prostigmine, and Acalypha indica (AI) Linn. compared with HR.
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respective receptor before being inactivated by acetylcholinesterase 
in the synaptic cleft (the space between nerve and muscle). Animal 
experiments show that MuSK immunoglobulin G (IgG) can cause MG. 
Mice that received repeated daily injections of patient IgG showed 
impaired neuromuscular transmission, with reductions in endplate 
AChR [18-20]. Similar changes to endplates were reported in mice, rats, 
and rabbits that were actively immunized with MuSK [21,22].
Driven by the fact that the pharmacological treatment of MG either can 
only treat the disease partially (anticholinesterases) or for other group 
of drugs (immunosuppressants) will result in major side effects, limited 
desired therapeutic effect from thymectomy, effects of intravenous (IV) 
Ig and plasmapheresis that can only last for short time, and enormously 
high cost of treatment, the needs, and urgency for alternative treatment 
for MG has become more and more important [23].
Many drugs used currently are expensive and may also have side 
effects on prolonged usage. These forced researchers to search drugs, 
which the price is relatively cheap, safe, and biodegradable, have fewer 
side effects and which will be able to act for longer periods before 
resistance sets in. Plants are the basic source of knowledge of modern 
medicine. Many studies have shown the role of herbal medicine used 
for the treatment of various diseases. Kassab et al. [24] found that the 
aqueous extract of clove (Syzygium aromaticum) has neuroprotective 
effects in rats with aluminum-induces neurotoxicity. Furthermore, 
Kukkar et al. [25] suggested that methanolic extract of Cardiospermum 
halicacabum Linn. might prove to be a useful memory restorative agent 
in the treatment of dementia seen in elderly.
Studies with the herbal plant in Indonesia were also developed for 
preventive and curative for MG. One of the therapeutic developments for 
MG is using herbal ingredients of Acalypha indica (AI). In the previous 
study, the water extract of the roots of AI for animal models proved to 
have a neuroprotective effect [26]. For his studies, mechanisms of plant 
AI as therapies on MG were done by assessing the autonomic condition 
on heart muscle will be tested. We want to know the effect extract of 
roots AI against the AChR and enzyme acetylcholinesterase in animal 
models NMJ-MG (Sprague-Dawley rats were injected with rocuronium 
bromide) on the autonomic nervous system on heart muscle, in this 
case, is heart rate (HR).
METHODS
Extraction process
The dry roots of AI were collected from Depok and had been identified 
at Lembaga Ilmu Pengetahuan (LIPI, Indonesian Institute of Sciences) 
Bogor. These roots were dried and powdered. The powder was 
macerated by ethanol 70% for 24 h. Subsequently, the residue was 
remacerated 3 times by the same solvent, and the extract was mixed 
with previous ones. The collected extract was then concentrated 
by rotary vacuum evaporator. The dose of AI in this study was 
150 mg/kg/body weight (BW). The extract was dissolved in aqua dest 
to get the appropriate dilution to administer orally just before the 
treatment exposure on each day.
Treatment
Animal involved in this experimental study was 36 Sprague-Dawley 
male rats, 8 w of age, and 150-200 g. The rats were adapted into the 
experimental cages at the room temperature of 24˚ C, for a week 
before and during treating. They were divided into six groups of an 
experiment, randomly. For this experiment used rocuronium (rocu), 
prostigmine (prost), and AI as compared with the HR. Rocuronium is 
a muscle relaxants non-depolarizing (competitive inhibitors) that bind 
to nicotinic-cholinergic receptors but does not cause depolarization, 
blocking acetylcholine, and occupied it, whereas prostigmine is a 
cholinesterase inhibitor used in the treatment of MG and to reverse 
the effects of muscle relaxants. Extract AI estimated can neutralize 
toxin caused by autoimmune and used as a therapy MG. Group control 
(normal) received CMC-Na Sol.1%.
The treatment divided into two set, AI as a curative treatment and AI as a 
preventive. As a curative treatment, rats divided into three groups. Rats 
in group rocu as injected with rocuronium intraperitoneal 10 mg/kg 
BW as a control negative; group rocu + pros was injected first with 
rocuronium then after 10 min injected with prostigmine (as a positive 
control); and group rocu + AI was injected first with rocuronium then 
after 10 min was given AI extract.
As a preventive, rats divided into three groups. Rats in group rocu 
as injected with rocuronium intraperitoneal 10 mg/kg BW, group 
pros + rocu was injected first with prostigmine then after 10 min injected 
with rocuronium; and group AI + rocu was given AI extract 250 mg/kg 
BW first then after 30 min was injected with rocuronium. The HR was 
measured 10 min after giving the treatment. The treatment was given 
for 3 days, at the end of day 3, each rat was sacrificed under anesthesia.
Statistical analysis
Calculations were done with the statistical package SPSS, version 12.0. 
Data were presented as a mean ± standard deviation. Unpaired 
two-sided Student’s t-test was utilized for comparison among means 
of normally distributed parameters, while Mann-Whitney U test was 
for all other cases. Correlations were assessed using Pearson’s and 
Spearman’s methods for normally and non-normally distributed data, 




The increase in HR (p=0.0302) occurred with injection rocu in control 
on day 1, while HR giving prostigmine in mice that received rocu first 
does not decrease significantly (p=0.5525) (Fig. 1a). Furthermore, the 
effects of injection rocu in group rocu + AI, HR increased significantly 
(p=0. 0137) and by given AI found a decline in HR but not significant 
(p=0.6205) (Fig. 1a).
Trial on the day 3, the effect of rocu on rocu group causes an increase 
in HR (p=0.0015), while the administration of rocu for the group rocu 
+ pros, HR found increased significantly (p=0.0142) but after giving 
prost, HR decreased not significant (p=0.3404) (Fig. 1c). In the group 
rocu + AI, HR rocu not significant (p=9646), and subsequently by AI, HR 
decreased but also not significant (p=0.8967) (Fig. 1c).
The increase in HR (p=0.0302) occurred with injection rocu in control 
on day 1, while HR giving rocu in mice that received prostigmine first 
as a preventive does not decrease significantly (p=0.0570) (Fig. 2a). 
Furthermore, the effects of injection rocu in mice that received AI first 
as a preventive, HR also was not increased significantly (p=0. 7525) 
(Fig. 2a).
On the 2nd day of trial found an increase in HR significantly (p=0.0019) 
in rocu group (Fig. 2b). While in the group prost + rocu, HR after giving 
rocu in mice that received prostigmine first as a preventive does not 
decrease significantly (p=0.4045) (Fig. 2b). Furthermore, the effects of 
injection rocu in mice that received AI first as a preventive, HR also was 
not increased significantly (p=0.4843) (Fig. 2b).
Trial on the day 3, the effect of rocu on rocu group causes an increase in 
HR (p=0.0015), while the administration of rocu in mice that received 
prostigmine first as a preventive does not increase (Fig. 2c). Furthermore, 
the effects of injection rocu in mice that received AI first as a preventive, 
HR also was not increased significantly (p=0.4843) (Fig. 2c).
On the 2nd day of trial found an increase in HR significantly (p=0.0019) 
in rocu group (Fig. 1b). Furthermore, in the group rocu + prost after the 
administration of rocu cause increased of HR significantly (p=0.0335), 
whereas  HR  after  injection  of  prostigmine  does  not 
decreased significant (p=0.5699) (Fig. 1b). Administration of rocu on 
group  rocu  +  AI  there  was  no  significant  increase  in  HR  (p=0.3762), 
and  then  after  giving  AI,  HR  did  not  occur  significant  differences 
(p=0.4235) (Fig. 1b).
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MG is a humoral immune attack to the skeletal muscle nicotinic AChRs 
(nAChRs) at the NMJ by autoantibodies [25]. The cardinal symptoms 
of MG is fatigue or fluctuating weakness in voluntary muscles with 
repeated or sustained exertion in the course of the day but improved 
by rest [27]. MG is an autoimmune disorder targeting skeletal muscles. 
Striated cardiac muscle can be a target for immune attack manifesting 
as heart failure, arrhythmia, and sudden death [28]. A few studies 
were carried out to investigate cardiac involvement in patients with 
MG. Some reported non-specific ECG changes, Doppler imaging, and 
conventional echocardiography [29]. Another study demonstrated a 
Fig. 1: Curative effect of Acalypha indica using prostigmine effect as a comparison. (a) Day 1 treatment, (b) Day 2 treatment, (c) Day 3 
treatment. Label*: Significantly different (P < 0.05)
c
ba
Fig. 2: Preventive effect of Acalypha indica using prostigmine effect as a comparison. (a) Day 1 treatment, (b) Day 2 treatment, (c) Day 3 
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reduced global heart ejection fraction in 40% of MG patients without 
known cardiac disease after exercise interpreted as a true association 
between MG and heart disease [30]. Depressed HR variability may be 
an early manifestation of autonomic neuropathy in patients with MG 
even in milder stages of the disease [4]. Heart muscle is a target for 
autoimmune inflammation in MG. Advancing age, thymoma, and anti-
Kv1 antibodies appeared to be risk factors. Symptom overlap with 
myasthenia may result in failure to recognize cardiac involvement [30].
CONCLUSION
AI Linn. has a similar effect with prostigmine as a positive control 
that can reduce HR although not significant in mice post-induction of 
rocuronium. AI Linn. also had the similar effect with prostigmine which 
could prevent an increase of HR in mice before rocuronium-induced. 
Our results clearly demonstrate AI as a promising candidate for the new 
agent for MG.
Our studies reported in this research were supported by grants from 
DRPM, Universitas Indonesia, No. 1782/UN2.R12/PPM.00.00/2016.
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AI Linn. has an effect similarly those that can lower HR with 
prostigmine  although  not  significant  in  mice  post-induction 
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increase in HR in rats will be induced by rocuronium. These results
 indicate the need for routine evaluation of autonomic functions 
in patients with MG both to identify patients at high risk for 
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up studies. Furthermore, on the basis of these results using 
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